Published in Vox Sang on January 01, 1972
Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest (1976) 2.84
HLA and rheumatoid arthritis: a combined analysis of 440 British patients. Ann Rheum Dis (1986) 1.66
B lymphocyte alloantigens in the study of the genetic basis of rheumatoid arthritis. Ann Rheum Dis (1977) 1.65
Follow-up study of juvenile chronic polyarthritis with particular reference to histocompatibility antigen W. 27. Ann Rheum Dis (1974) 1.55
The association between rheumatoid arthritis and the HLA antigen DR4. Ann Rheum Dis (1983) 1.21
The cytotoxicity of leukocytes and lymphocytes from patients with rheumatoid arthritis for synovial cells. J Clin Invest (1976) 0.89
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis (2000) 2.34
Solitary myeloma: clinical and prognostic features of a review of 114 cases. Cancer (1981) 2.23
Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum (2001) 2.00
Endocarditis associated with ANCA. Clin Exp Rheumatol (1994) 1.85
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Increased percentage of CD3+, CD57+ lymphocytes in patients with rheumatoid arthritis. Correlation with duration of disease. Arthritis Rheum (1993) 1.63
Inflammatory joint disease after immunizations. A report of two cases. Rev Rhum Engl Ed (1997) 1.61
Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis Rheum (1990) 1.51
Effect of etanercept on tenosynovitis and nodules in rheumatoid arthritis. Arthritis Rheum (2002) 1.48
Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol (1995) 1.46
Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue. Clin Exp Immunol (1998) 1.45
Polymorphism of the HLA-DMA and DMB genes in rheumatoid arthritis. Arthritis Rheum (1997) 1.44
Immunological aspects of psoriasis. II. Dissociated impairment of thymus-dependent lymphocytes. Br J Dermatol (1976) 1.44
Gene transfer to human rheumatoid synovial tissue engrafted in SCID mice. J Rheumatol (1997) 1.43
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis (2006) 1.42
[Low-dose antithymocyte globulins in kidney transplantation: results of a protocol of intermittent administration]. Nephrologie (2000) 1.40
CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS (2001) 1.38
Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest (1991) 1.38
Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol (1989) 1.33
The relation of parental sex and age to recombination in the HL-A system. Hum Hered (1973) 1.30
Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol (1998) 1.29
Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis (2004) 1.29
Radiologic progression in early rheumatoid arthritis treated with methotrexate. J Rheumatol (1999) 1.27
Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients. Blood (1984) 1.26
The AIMS2-SF: a short form of the Arthritis Impact Measurement Scales 2. French Quality of Life in Rheumatology Group. Arthritis Rheum (1997) 1.26
Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol (1999) 1.25
Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis (1996) 1.23
Acute osteoporotic vertebral collapse: open study on percutaneous injection of acrylic surgical cement in 20 patients. AJR Am J Roentgenol (1999) 1.23
The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol (2006) 1.21
Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis (2007) 1.14
Age-dependent changes of human blood lymphocyte subpopulations. Clin Exp Immunol (1978) 1.10
Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damage. Ann Rheum Dis (1997) 1.09
Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer (1990) 1.07
Investigation of the HLA component involved in rheumatoid arthritis (RA) by using the marker association-segregation chi-square (MASC) method: rejection of the unifying-shared-epitope hypothesis. Am J Hum Genet (1993) 1.07
Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol (1986) 1.07
Rheumatoid nodulosis: report of two new cases and discussion of diagnostic criteria. J Rheumatol (1988) 1.06
Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis. Ann Rheum Dis (1999) 1.06
WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.06
New concepts in the pathogenesis of psoriasis. Br J Dermatol (1978) 1.06
Atlanto-axial dislocation in rheumatoid arthritis. Rheumatism (1966) 1.05
[Nerve compressions in tabetic arthropathy of the spine]. Bull Acad Natl Med (1970) 1.04
Objective and subjective sleep disturbances in patients with rheumatoid arthritis. A reappraisal. Arthritis Rheum (1994) 1.04
Immunological aspects of psoriasis. I. Immunoglobulins and anti-IgG factors. Br J Dermatol (1976) 1.03
[Uric acid inhibitors in the treatment of gout. Apropos of 126 cases]. Sem Hop (1970) 1.03
Interleukin-1 release by alveolar macrophages in asthmatic patients and healthy subjects. Int Arch Allergy Appl Immunol (1990) 1.02
Sensitivity of magnetic resonance imaging of the wrist in very early rheumatoid arthritis. Clin Exp Rheumatol (1993) 1.01
Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol (1996) 1.01
Modulation of the immune response by the neuro-endocrine axis in rheumatoid arthritis. Clin Exp Rheumatol (1994) 1.00
HL-A in Graves' disease and in diabetes mellitus insulin-dependent. Tissue Antigens (1975) 1.00
Clinical significance of antibodies to soluble extractable nuclear antigens (anti-ENA). Ann Rheum Dis (1978) 1.00
Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheumatol (1995) 0.99
Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue diseases. Clin Exp Immunol (1989) 0.99
Stimulation of lymphocytes from rheumatoid arthritis patients by mitogens and IgG. Allerg Immunol (Leipz) (1976) 0.98
[Hyperparathyroidiem and articular chondrocalcinosis]. J Belge Rhumatol Med Phys (1967) 0.97
Inhibitory effect of Australia-positive sera on in-vitro-stimulated T lymphocytes. Lancet (1973) 0.97
[Muscular manifestations of human cysticercosis]. Rhumatologie (1970) 0.97
Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum (1994) 0.97
beta 2-Microglobulin and beta 2-microglobulin-binding proteins in inflammatory diseases. Eur J Rheumatol Inflamm (1982) 0.96
In Vitro studies on human B and T cell purified populations. Stimulation by mitogens and allogeneic cells, and quantitative binding of phytomitogens. Immunology (1975) 0.95
Evaluation of lymphocyte subpopulations and T-cell functions in psoriasis. Clin Immunol Immunopathol (1978) 0.95
Non-Hodgkin's lymphoma associated with primary Sjögren's syndrome. Eur J Med (1992) 0.94
The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment. Br J Dermatol (2005) 0.94
Sicca syndrome associated with hepatitis C virus infection. Arthritis Rheum (1996) 0.94
T cell receptor expression and activation of synovial lymphocyte subsets in patients with rheumatoid arthritis. Phenotyping of multiple synovial sites. Arthritis Rheum (1990) 0.94
Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo. Immunology (1998) 0.93
Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status. Eur J Cancer Clin Oncol (1982) 0.92
Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol (1997) 0.92
Arthritis associated with monoclonal gammapathy: clinical characteristics. Br J Rheumatol (1996) 0.92
DNA polymorphism related to HLA-DR2 Dw2 in patients with narcolepsy. Immunogenetics (1985) 0.91
[Arthropathy with achilles tendon involvement induced by pefloxacin. Apropos of a case]. Rev Rhum Mal Osteoartic (1991) 0.91
Circulating lymphocyte subpopulations in juvenile insulin-dependent diabetes. Correction of abnormalities by adequate blood glucose control. Diabetologia (1979) 0.91
Differential transcriptional activities of HLA-DR genes in the various haplotypes. J Immunol (1994) 0.91
Quantitative analysis of the expression of the HLA-DRB genes at the transcriptional level by competitive polymerase chain reaction. J Immunol (1996) 0.90
Immunomodulating effect of human placenta-eluted gamma globulins in rheumatoid arthritis. Arthritis Rheum (1982) 0.90
Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer (1986) 0.90
Psoriatic arthritis and HLA antigens. J Rheumatol Suppl (1977) 0.89
Letter: HL-A and pernicious anemia. N Engl J Med (1975) 0.89
Synergistic effect of two HLA heterodimers in the susceptibility to celiac disease in Tunisia. Genet Epidemiol (1997) 0.88
Treatment of infantile spasms with intravenous gamma-globulins. Brain Dev (1991) 0.88
Human placenta-eluted gammaglobulins in immunomodulating treatment of rheumatoid arthritis. Am J Med (1985) 0.88
Anti-IgG activity on peripheral blood lymphocytes in psoriasis. Arch Dermatol (1973) 0.88
Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol (1997) 0.88
[Anemia in rheumatoid polyarthritis. Value of serum ferritin for the estimation of iron stores]. Nouv Presse Med (1982) 0.88
[Destructive lesions of the disks and the vertebral bodies during the course of ankylosing spondylarthritis]. J Radiol Electrol Med Nucl (1966) 0.87
[Serum beta-2-microglobulin in multiple myeloma. Practical value]. Rev Rhum Mal Osteoartic (1981) 0.87
Dysregulation of the hypothalamo-pituitary axis in rheumatoid arthritis. J Rheumatol (1995) 0.87
Cryocrystalglobulinemia as a cause of systemic vasculopathy and widespread erosive arthropathy. Arthritis Rheum (1996) 0.86
Mononuclear cell retention in rheumatoid synovial tissue engrafted in severe combined immunodeficient (SCID) mice is up-regulated by tumour necrosis factor-alpha (TNF-alpha) and mediated through intercellular adhesion molecule-1 (ICAM-1). Clin Exp Immunol (1996) 0.86
Interleukin 2 (IL 2) inhibitor in rheumatoid synovial fluid: correlation with prognosis and soluble IL 2 receptor levels. J Clin Immunol (1990) 0.86